Presentation of BMP-2 mimicking peptides in 3D hydrogels directs cell fate commitment in osteoblasts and mesenchymal stem cells

Biomacromolecules

Volumn 15, Issue 2, 2014, Pages 445-455

  Madl, Christopher M ^a,e   Mehta, Manav ^a,b,c   Duda, Georg N ^c   Heilshorn, Sarah C ^d   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Stanford University   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINATE HYDROGELS; ALKALINE PHOSPHATASE ACTIVITY; BIOMATERIAL SCAFFOLDS; BONE MORPHOGENETIC PROTEIN-2; FLUORESCENTLY LABELING; H NMR SPECTROSCOPY; MESENCHYMAL STEM CELL; MINERAL DEPOSITIONS;

BIOLOGICAL MATERIALS; BIOSYNTHESIS; CELL CULTURE; HYDROGELS; PEPTIDES; PHOSPHATASES; STEM CELLS; THREE DIMENSIONAL; TWO DIMENSIONAL;

SCAFFOLDS (BIOLOGY);

ALGINIC ACID; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CYANAMIDE; HYDRAZIDE; MALEIMIDE; OSTEOPONTIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SMAD PROTEIN; THIOL DERIVATIVE; BIOMIMETIC MATERIAL; BMP2 PROTEIN, HUMAN; HYDROGEL; PEPTIDE; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; CELL FATE; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; ENCAPSULATION; ENZYME ACTIVITY; HYDROGEL; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST; OSTEOPROGENITOR CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; SOLID PHASE SYNTHESIS; SURFACE PROPERTY; UPREGULATION; BONE DEVELOPMENT; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; HUMAN; MESENCHYMAL STROMA CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOLOGY; SYNTHESIS;

BIOMIMETIC MATERIALS; BONE MORPHOGENETIC PROTEIN 2; CELLS, CULTURED; HUMANS; HYDROGELS; MAGNETIC RESONANCE SPECTROSCOPY; MESENCHYMAL STROMAL CELLS; MOLECULAR STRUCTURE; OSTEOBLASTS; OSTEOGENESIS; PEPTIDES; RECOMBINANT PROTEINS;

EID: 84896775312     PISSN: 15257797     EISSN: 15264602     Source Type: Journal    
DOI: 10.1021/bm401726u     Document Type: Article

References (39)

1. Caplan, A. I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell. Physiol. 2007, 213, 341-347.
2. Pountos, I.; Corscadden, D.; Emery, P.; Giannoudis, P. V. Mesenchymal stem cell tissue engineering: Techniques for isolation, expansion and application. Injury 2007, 38(Supplement 4), S23-S33.
3. Mooney, D. J.; Vandenburgh, H. Cell delivery mechanisms for tissue repair. Cell Stem Cell 2008, 2, 205-211.
4. Silva, E. A.; Kim, E.-S.; Kong, H. J.; Mooney, D. J. Material-based deployment enhances efficacy of endothelial progenitor cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 14347-14352.
5. Sittinger, M.; Hutmacher, D. W.; Risbud, M. V. Current strategies for cell delivery in cartilage and bone regeneration. Cur. Opin. Biotechnol. 2004, 15, 411-418.
6. Mehta, M.; Schmidt-Bleek, K.; Duda, G. N.; Mooney, D. J. Biomaterial delivery of morphogens to mimic the natural healing cascade in bone. Adv. Drug Delivery Rev. 2012, 64, 1257-1276.
7. Cahill, K. S.; Chi, J. H.; Day, A.; Claus, E. B. Prevalence, complications, and hospital charges associated with use of bonemorphogenetic proteins in spinal fusion procedures. J. Am. Med. Assoc. 2009, 302, 58-66.
8. Haid, R. W.; Branch, C. L.; Alexander, J. T.; Burkus, J. K. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004, 4, 527-539.
9. Wong, D. A.; Kumar, A.; Jatana, S.; Ghiselli, G.; Wong, K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2008, 8, 1011-1018.
10. Smucker, J.; Rhee, J.; Singh, K.; Yoon, S.; Heller, J. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine 2006, 31, 2813-2819.
11. Shields, L. B.; Raque, G. H.; Glassman, S. D.; Campbell, M.; Vitaz, T.; Harpring, J.; Shields, C. B. Adverse effects associated with high dose rhBMP-2 use in anterior cervical spine fusion. Spine 2006, 31, 542-547.
12. Garrison, K.; Donell, S.; Ryder, J.; Shemilt, I.; Mugford, M.; Harvey, I.; Song, F. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technology Assessment 2007, 11.
13. Ruoslahti, E.; Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238, 491-497.
14. Hsiong, S. X.; Huebsch, N.; Fischbach, C.; Kong, H. J.; Mooney, D. J. Integrin-adhesion ligand bond formation of preosteoblasts and stem cells in three-Dimensional RGD presenting matrices. Biomacromolecules 2009, 9, 1843-1851.
15. Fan, V. H.; Au, A.; Tamama, K.; Littrell, R.; Richardson, L. B.; Wright, J. W.; Wells, A.; Griffith, L. G. Tethered EGF provides a survival advantage to mesenchymal stem cells. Stem Cells 2007, 25, 1241-1251.
16. Saito, A.; Suzuki, Y.; Ogata, S.-I.; Ohtsuki, C.; Tanihara, M. Activation of osteo-progenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope. Biochim. Biophys. Acta 2003, 1651, 60-67.
17. Lee, J.-Y.; Choo, J.-E.; Choi, Y.-S.; Suh, J.-S.; Lee, S.-J.; Chung, C.-P.; Park, Y.-J. Osteoblastic differentiation of human bone marrow stromal cells in self-assembled BMP-2 receptor-binding peptideamphiphiles. Biomaterials 2009, 30, 3532-3541.
18. D'Andrea, L. D.; Iaccarino, G.; Fattorusso, R.; Sorriento, D.; Carannante, C.; Capasso, D.; Trimarco, B.; Pedone, C. Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 14215-14220.
19. Lin, X.; Takahashi, K.; Campion, S. L.; Liu, Y.; Gustavsen, G. G.; Pena, L. A.; Zamora, P. O. Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo. Int. J. Mol. Med. 2006, 17, 833-839.
20. Manfe, V.; Kochoyan, A.; Bock, E.; Berezin, V. Peptides derived from specific interaction sites of the fibroblast growth factor 2: FGF receptor complexes induce receptor activation and signaling. J. Neurochem. 2010, 114, 74-86.
21. Kirkwood, K.; Rheude, B.; Kim, Y. J.; White, K.; Dee, K. C. In vitro mineralization studies with substrate-immobilized bone morphogenetic protein peptides. J. Oral Implantol. 2003, 29, 57-65.
22. Huebsch, N.; Arany, P. R.; Mao, A. S.; Shvartsman, D.; Ali, O. A.; Bencherif, S. A.; Rivera-Feliciano, J.; Mooney, D. J. Harnessing traction-mediated manipulation of the cell/matrix interface to control stem-cell fate. Nat. Mater. 2010, 9, 518-526.
23. Rowley, J. A.; Madlambayan, G.; Mooney, D. J. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1999, 20, 45-53.
24. Senta, H.; Park, H.; Bergeron, E.; Drevelle, O.; Fong, D.; Leblanc, E.; Cabana, F.; Roux, S.; Grenier, G.; Faucheux, N. Cell responses to bone morphogenetic proteins and peptides derived from them: Biomedical applications and limitations. Cytokine Growth Factor Rev. 2009, 20, 213-222.
25. De Gorter, D. J. J.; Van Bezooijen, R. L.; Ten Dijke, P. Bone morphogenetic proteins and their receptors. Encycl. Life Sci. 2009, 1. 9.
26. Lee, J. S.; Lee, J. S.; Murphy, W. L. Modular peptides promote human mesenchymal stem cell differentiation on biomaterial surfaces. Acta Biomater. 2010, 6, 21-28.
27. Moore, N. M.; Lin, N. J.; Gallant, N. D.; Becker, M. L. Synergistic enhancement of human bone marrow stromal cell proliferation and osteogenic differentiation on BMP-2-derived and RGD peptide concentration gradients. Acta Biomater. 2011, 7, 2091-2100.
28. Comisar, W. A.; Hsiong, S. X.; Kong, H.-J.; Mooney, D. J.; Linderman, J. J. Multi-scale modeling to predict ligand presentation within RGD nanopatterned hydrogels. Biomaterials 2006, 27, 2322-2329.
29. Kumagai, H.; Tajima, M.; Ueno, Y.; Giga-Hama, Y.; Ohba, M. Effect of cyclic RGD peptide on cell adhesion and tumor metastasis. Biochem. Biophys. Res. Commun. 1991, 177, 74-82.
30. Hsiong, S. X.; Boontheekul, T.; Huebsch, N.; Mooney, D. J. Cyclic arginine-glycine-aspartate peptides enhance three-dimensional stem cell osteogenic differentiation. Tissue Eng., Part A 2009, 15, 263-272.
31. Patel, G.; Husman, W.; Tehanli, A. M.; Deadman, J. J.; Green, D.; Kakkar, V. V.; Brennand, D. M. A cyclic peptide analogue of the loop III region of platelet derived growth factor-BB is a synthetic antigen for the native protein. J. Pept. Res. 1999, 53, 68-74.
32. Colangelo, A. M.; Bianco, M. R.; Vitagliano, L.; Cavaliere, C.; Cirillo, G.; Gioia, L. D.; Diana, D.; Colombo, D.; Redaelli, C.; Zaccaro, L.; Morelli, G.; Papa, M.; Sarmientos, P.; Alberghina, L.; Martegani, E. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J. Neurosci. 2008, 28, 2698-2709.
33. Brown, M. A.; Zhao, Q.; Baker, K. A.; Naik, C.; Chen, C.; Pukac, L. Crystal structure of BMP-9 and functional interactions with proregion and receptors. J. Biol. Chem. 2005, 280, 25111-25118.
34. Lee, K. Y.; Alsberg, E.; Hsiong, S. X.; Comisar, W. A.; Linderman, J. J.; Ziff, R.; Mooney, D. J. Nanoscale adhesion ligand organization regulates osteoblast proliferation and differentiation. Nano Lett. 2004, 4, 1501-1506.
35. Comisar, W. A.; Kazmers, N. H.; Mooney, D. J.; Linderman, J. J. Engineering RGD nanopatterned hydrogels to control preosteoblast behavior: A combined computational and experimental approach. Biomaterials 2007, 28, 4409-4417.
36. Wall, S. T.; Saha, K.; Ashton, R. S.; Kam, K. R.; Schaffer, D. V.; Healy, K. E. Multivalency of Sonic Hedgego Conjugated to Linear Polymer Chains Modulates Protein Potency. Bioconjugate Chem. 2008, 19, 806-812.
37. Guo, X.; Wang, X.-F. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res. 2009, 19, 71-88.
38. Saito, A.; Suzuki, Y.; Ogata, S.-I.; Ohtsuki, C.; Tanihara, M. Prolonged ectopic calcification induced by BMP-2.derived synthetic peptide. J. Biomed. Mater. Res., Part A 2004, 70, 115-121.
39. Li, J.; Hong, J.; Zheng, Q.; Guo, X.; Lan, S.; Cui, F.; Pan, H.; Zou, Z.; Chen, C. Repair of rat cranial bone defects with nHAC/PLLA and BMP-2-related peptide or rhBMP-2. J. Orthop. Res. 2011, 29, 1745-1752.